Effects of agomelatine combined with venlafaxine and placebo on levels of BDNF,5-HT,FGF-22 and ACTH in elderly patients with depression
Objective To analyze the effects of agomelatine combined with venlafaxine and pla-cebo on the levels of brain-derived nerve growth factor(BDNF),serotonin(5-HT),fibroblast growth factor-22(FGF-22)and adrenocorticotropic hormone(ACTH)in elderly patients with depression.Methods 110 elderly patients with depression were admitted to the Seventh People's Hospital of Hengshui City from January 2022 to June 2023.They were divided into two groups:group A(agomelatine combined with a placebo,n=55)and group B(agomelatine combined with venlafaxine,n=55)using the random number table method.All patients received continuous treatment for 12 weeks.The clinical efficacy after 12 weeks of treatment,levels of serum BDNF,5-HT,FGF-22,ACTH,heart rate variability index,scores of the Wechsler Adult Memory Scale(WMS-RC)before and after 12 weeks of treatment,Hamilton Depression Scale(HAMD)and Pittsburgh Sleep Quality Index(PSQI)at different time points were compared between the two groups.Results The clinical to-tal effective rate in group B was higher than that in group A,and the difference was statistically significant(P<0.05).Compared to before treatment,the levels of serum ACTH in both groups decreased.Additionally,the lev-els of serum BDNF,5-HT,FGF-22,total value of frequency domain(TP),standard deviation of normal RR interval(SDNN),high frequency(HF),low frequency(LF)and WMS-RC all increased in group B,and the differences were statistically significant(P<0.05).Compared to before treatment,after 3 to 12 weeks of treat-ment,the scores of HAMD and PSQI in both groups gradually decreased.The difference in group B was lower than that in group A(P<0.05).Conclusion The combination of agomelatine and venlafaxine could enhance the heart rate variability,regulate levels of nervous system related factors,improve sleep quality,reduce depres-sion,and enhance cognitive function.
NETL
NSTL
万方数据
